Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor

被引：20

作者：

Imaeda, Yasuhiro ^{[1
]}

Tokuhara, Hidekazu ^{[1
]}

Fukase, Yoshiyuki ^{[1
]}

Kanagawa, Ray ^{[1
]}

Kajimoto, Yumiko ^{[1
]}

Kusumoto, Keiji ^{[1
]}

Kondo, Mitsuyo ^{[1
]}

Snell, Gyorgy ^{[2
]}

Behnke, Craig A. ^{[2
,3
]}

Kuroita, Takanobu ^{[1
]}

机构：

[1] Takeda Pharmaceut Co Ltd, Pharmaceut Res Div, 26-1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 2518555, Japan

[2] Takeda Calif Inc, 10410 Sci Ctr Dr, San Diego, CA 92121 USA

[3] Sapphire Energy Inc, 9363 Towne Ctr Dr, San Diego, CA 92121 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2016年 / 7卷 / 10期

基金：

美国国家卫生研究院;

关键词：

Renin inhibitor; TAK-272; benzimidazole; hypertension; SBDD; dTg rat; HYPERTENSION; PIPERIDINES; EFFICIENCY; ALISKIREN; DESIGN; SYSTEM;

D O I：

10.1021/acsmedchemlett.6b00251

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The aspartic proteinase renin is an attractive target for the treatment of hypertension and cardiovascular/renal disease such as chronic kidney disease and heart failure. We introduced an S1' site binder into the lead compound 1 guided by structure-based drug design (SBDD), and further optimization of physicochemical properties led to the discovery of benzimidazole derivative 10 (1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-yl)carbonylpiperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride, TAK-272) as a highly potent and orally active renin inhibitor. Compound 10 demonstrated good oral bioavailability (BA) and long-lasting efficacy in rats. Compound 10 is currently in clinical trials.

引用

页码：933 / 938

页数：6

共 50 条

[1] Differences in nonclinical pharmacokinetics between species and prediction of human pharmacokinetics of TAK-272 (SCO-272), a novel orally active renin inhibitor
Ebihara, Takuya
Nishihara, Mitsuhiro
Takahashi, Junzo
Jinno, Fumihiro
Tagawa, Yoshihiko
BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (03) : 175 - 183
[2] The effect of elevated α1-acid glycoprotein on the pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, in rats
Ebihara, Takuya
Shimizu, Hisao
Yamamoto, Masami
Higuchi, Tomoaki
Jinno, Fumihiro
Tagawa, Yoshihiko
XENOBIOTICA, 2019, 49 (05) : 584 - 590
[3] TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model
Hara, Tomoya
Nishimura, Satoshi
Yamamoto, Toshihiro
Kajimoto, Yumiko
Kusumoto, Keiji
Kanagawa, Ray
Ikeda, Shota
Nishimoto, Tomoyuki
PLOS ONE, 2018, 13 (08):
[4] Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor
Iijima, Daisuke
Sugama, Hiroshi
Takahashi, Yoichi
Hirai, Miki
Togashi, Yuko
Xie, Jianshu
Shen, Jingkang
Ke, Ying
Akatsuka, Hidenori
Kawaguchi, Takayuki
Takedomi, Kei
Kashima, Akiko
Nishio, Masashi
Inui, Yosuke
Yoneda, Hikaru
Xia, Guangxin
Iijima, Toru
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (16) : 10882 - 10897
[5] SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF SINGLE DOSES OF TAK-272, A NOVEL RENIN INHIBITOR, IN HEALTHY MALE SUBJECTS
Matsuno, K.
Kuroda, S.
Tanaka, S.
Nakamichi, H.
Komura, E.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
[6] A NOVEL NONPEPTIDIC, ORALLY ACTIVE RENIN INHIBITOR
MORISHIMA, H
KOIKE, Y
NAKANO, M
ATSUUMI, S
TANAKA, S
FUNABASHI, H
HASHIMOTO, J
SAWASAKI, Y
MINO, N
NAKANO, M
MATSUSHIMA, K
NAKAMICHI, K
YANO, M
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 159 (03) : 999 - 1005
[7] Discovery and development of anacetrapib, a potent and orally active CETP inhibitor
Ali, Amjad
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
[8] Excretion and metabolism of remikiren, a potent orally active inhibitor of primate renin
Jauch, R
Schmid, P
Fischli, W
Meister, W
Maurer, R
Wendt, G
XENOBIOTICA, 1996, 26 (03) : 285 - 295
[9] AN ORALLY ACTIVE INHIBITOR OF RENIN
PALS, DT
THAISRIVONGS, S
LAWSON, JA
KATI, WM
TURNER, SR
DEGRAAF, GL
HARRIS, DW
JOHNSON, GA
HYPERTENSION, 1986, 8 (12) : 1105 - 1112
[10] DISCOVERY OF REMIKIREN AS THE 1ST ORALLY ACTIVE RENIN INHIBITOR
CLOZEL, JP
FISCHLI, W
ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1993, 43-1 (2A): : 260 - 262

← 1 2 3 4 5 →